Home / Biotechnology / High Throu

High Throughput Screening Market By Technology Type (Cell Based Assays, Ultra High Throughput Screening, Lab-on-a-Chip, Bioinformatics, Label Free Technology), By Application (Target Identification, Primary & Secondary Screening, Toxicology Assessment, Others), By End User (Biotechnology & Pharmaceutical Industries, Academic & Government Research Institutes, Contract Research Organizations, Others) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

High throughput screening market to exhibit productive growth during the forecast period.

The global high-throughput screening (HTS) market is expanding rapidly, with a value of US$ 13.2 billion in 2017 and a projected value of US$ 24.4 billion by 2026. The increasing need for drug discovery in pharmaceuticals and biotechnology will enhance the overall expansion of the high-throughput screening market globally.

New technology assessment in the field of cell-based assays is significant; the fluorometric imaging plate reader and cell-based assays will drive the market in developed nations. New automated platforms for ultra-high throughput screening will gain traction globally. Additionally, the adoption of advanced testing and detection platforms, utilization of 3D-based cultures, and better funding from research organizations or public sources will further spur revenue growth during the forecast period.

The easy affordability of novel automated platforms, the increasing need for new therapies, and rapid new product launches are factors driving the HTS market growth in developed countries. Nevertheless, the high cost of automated systems, lack of infrastructure, and economic issues associated with complex HTS and R&D are a few factors limiting the growth of the high throughput screening market globally.

Market Synopsis

Ultra-high throughput screening (uHTS) in drug discovery is expected to register higher growth by 2026.

High-throughput screening technologies are categorized into cell-based assays, ultra-high-throughput screening, lab-on-a-chip, bioinformatics, and label-free technology. The growing number of drug targets for primary and secondary screening, as well as research funding from the government, private sector, and research institutes, are boosting overall growth in developed countries.

Current trends show improvements in chemical libraries and advanced software, along with automation techniques with high standards and enhanced outcomes via screening procedures. The increasing need for newer treatments for a number of disease conditions is supporting new technology assessments in high-throughput screening.

Currently, drug discovery platforms with ultra-high throughput screening are well-defined by screening numbers. However, the high cost and low efficiency of advanced software for liquid handling systems, plate reader detection, and automated robotic arms have a negative impact on the market.

Drug discovery platforms to witness a significant CAGR

The high-throughput screening techniques are utilized in various application areas, such as target identification, primary and secondary screening, toxicology assessment, and others. Pharmaceutical and biotech companies have funded a wide scale of automated systems to increase the adoption of throughput screening across the early stages of drug discovery processes.

Maximum revenue share is being generated by the increased use of ultra-high-throughput screening and advanced robotic platforms. Additionally, noteworthy developments in specialized instrumentation, such as multi-mode microplate readers, will gain traction globally. HTS processes have evolved to carry out various procedures in an automated environment using a custom-engineered 3D imaging system.

For instance, in November 2018, NTRC (the Netherlands Translational Research Center) launched the first high-throughput screening assay for arginase-1 inhibitors at ENA2018. Other applications, such as automating target-based and complex phenotypic drug discovery, cytotoxicity detection, and advanced primary screening in cell-based assays, show promising opportunities during the forecast period.

Increasing applications in biotechnology and the pharmaceutical industry witness a significant CAGR.

High-throughput screening processes are utilized in various areas, with prime occupations in pharmaceuticals and biotechnology. Due to the numerous technology assessments taking place on drug discovery platforms, various small and medium-sized pharmaceutical and biotech companies are intensively focused on the development of novel molecules for numerous life-threatening disorders.

Moreover, huge investments in the biotech and pharmaceutical industries for high-throughput screening technology in terms of miniaturization, automation, and assay methodology have helped spur market growth globally. Additionally, the end-users of the HTS market have perceived a growing number of clinical candidates and marketed drugs arising from the advanced techniques utilized.

High demand, new product launches, and the presence of top players hold North America in a dominant position.

At present, North America (dominantly the U.S.) generates the maximum market share in the global market, thanks to new product launches and advanced automation techniques. Convenient access to HTS laboratories facilitating advanced assay technologies for performing primary and secondary screening campaigns is on the rise in the U.S.

Other prominent factors leading the market's growth include the demand for extensive automation techniques in HTS, increased research and development activities on toxicology and stem cells, and the integration of advanced data management and information systems. However, high costs, limited availability of automated systems, a lack of trained staff, and complexity in assay development and techniques are limiting the growth of the HTS market.

The dominance of multinational manufacturers with strong product portfolios in the developed regions

Major players in the high-throughput screening market are Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories; Agilent Technologies, Inc.; Tecan Group Ltd.; Aurora Biomed; Perkinelmer, Inc.; Sigma Aldrich Corporation; Axxam Spa; Hamilton Company; Aurora Biomed, Inc.; Danaher Corporation; Beckman Coulter, Inc.; GE Healthcare; and others. Top companies are producing high-throughput screening in a highly automated environment. Additionally, partnerships with other companies, research organizations, and academic institutes will further drive the market's growth.

For instance, in February 2018, Charles River Laboratories declared a new agreement that grants commercial access to AstraZeneca's high-throughput screening systems and compound management infrastructure. The company will perform high-throughput screening programs by utilizing AstraZeneca's hi-tech HTS facility.

Periods of History and Forecast

This study report includes an analysis for each segment from 2016 to 2026, with 2017 as the base year. The compound annual growth rate (CAGR) for each of the respective segments is estimated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report also encompasses qualitative market valuation factors such as key market drivers, market trends, restraints, and opportunities that give a better understanding of the overall high-throughput screening market. Additionally, the report also comprises a graphical representation of the competitive landscape based on their market initiatives and strategies, product portfolios, and business strengths.

Key questions are answered in this report.

  • What are the current and future trends in high-throughput screening?
  • What are the current dynamics in automated systems, as well as the valuable opportunities for new entrants?
  • Which application segment accounts for the fastest CAGR during the forecast period?
  • Which end-user type holds a larger market share and why?
  • What is the impact of the high cost of automated systems in the high-throughput screening market?
  • What are the products and brands in the HTS industry that are growing most significantly, and why?
  • What is the impact of information systems on the global market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and the Middle East and Africa?

Frequently Asked Question:

The market for High Throughput Screening Market is expected to reach USD$ 24.4 Bn in 2026.

The High Throughput Screening Market is expected to see significant CAGR growth over the coming years, at XX%.

The report is forecasted from 2018 -2026.

The base year of this report is 2017.

Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories; Agilent Technologies, Inc.; Tecan Group Ltd.; Aurora Biomed; Perkinelmer, Inc.; Sigma Aldrich Corporation. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Nov 2018
Category:  Biotechnology
Report ID:   59450
Report Format:   PDF
Pages:   120
Rating:    4.2 (58)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support